Publications by authors named "Marieke Bolkenbaas"
Article Synopsis
- The study aimed to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for preventing community-acquired pneumonia (CAP) and lower respiratory tract infections (LRTI) in adults over 65.
- In a trial with over 40,000 participants, those who received PCV13 showed very little benefit in terms of reducing CAP and LRTI incidents or antibiotic prescriptions compared to the placebo group.
- Ultimately, the findings suggest that PCV13 vaccination in older adults is unlikely to significantly lower the rates of CAP, LRTI, or antibiotic use in primary care settings.
Background: The 13-valent pneumococcal conjugate-vaccine (PCV13) was effective in preventing vaccine-type Community-Acquired Pneumonia (VT-CAP) and Invasive Pneumococcal Disease (VT-IPD) in elderly subjects, but vaccine efficacy (VE) in patients with comorbidities at time of vaccination is unknown.
Methods: This is a post hoc analysis of the CAPiTA study, a double blind, randomized controlled trial with 84,496 immunocompetent participants aged ⩾65years, receiving PCV13 or placebo vaccination. Presence of diabetes mellitus (DM), heart disease, respiratory disease, liver disease, asplenia, and smoking at the time of immunization was verified on medical records in 139 subjects developing the primary endpoint of VT-CAP.
Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L.
Health Qual Life Outcomes
January 2017
Article Synopsis
- - This study assessed the health status of elderly individuals living in the community in the Netherlands, examining factors like demographics and comorbidities using a specific health measurement tool (EQ-5D-3L).
- - A significant sample size of 48,634 elderly participants revealed common health complaints, with pain being prevalent among younger seniors and mobility issues affecting older elderly individuals (aged 85+).
- - Findings indicated that health status declines with age and is further influenced by factors such as gender, education level, location, and the presence of additional health conditions.
Background: Herd protection from infant pneumococcal conjugate vaccination is well established for invasive pneumococcal disease (IPD) but not for non-IPD pneumococcal community-acquired pneumonia (PCAP). We assessed the contribution of vaccine-serotypes in non-IPD PCAP in adults 65 years and older in the period 2008-2013.
Methods: This is a post hoc analysis of two prospective studies from the Netherlands.
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
View Article and Find Full Text PDFBackground: Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is unknown.
Methods: In a randomized, double-blind, placebo-controlled trial involving 84,496 adults 65 years of age or older, we evaluated the efficacy of 13-valent polysaccharide conjugate vaccine (PCV13) in preventing first episodes of vaccine-type strains of pneumococcal community-acquired pneumonia, nonbacteremic and noninvasive pneumococcal community-acquired pneumonia, and invasive pneumococcal disease. Standard laboratory methods and a serotype-specific urinary antigen detection assay were used to identify community-acquired pneumonia and invasive pneumococcal disease.